Resultado da Busca
F Zhang, LP Wang, M Brauner, JF Liewald, K Kay, N Watzke, PG Wood, ... Nature 446 (7136), 633-639. , 2007. 2150. 2007. Articles 1–20. HHMI / Massachusetts Institute of Technology / Broad...
Feng Zhang is a molecular biologist and a core institute member of the Broad Institute, where he develops and applies genome editing tools for studying the brain and human diseases. He is also an investigator at the McGovern Institute, the James and Patricia Poitras Professor of Neuroscience at MIT, and a professor at MIT.
Feng Zhang (Chinese: 张锋; pinyin: Zhāng Fēng; born October 22, 1981) is a Chinese–American biochemist. Zhang currently holds the James and Patricia Poitras Professorship in Neuroscience at the McGovern Institute for Brain Research and in the departments of Brain and Cognitive Sciences and Biological Engineering at the ...
Dr. Zhang is a molecular biologist focused on improving human health. He played an integral role in the development of two revolutionary technologies, optogenetics and CRISPR-Cas systems, including pioneering the use of Cas9 for genome editing and discovering CRISPR-Cas12 and Cas13 systems and developing them for therapeutic and diagnostic ...
Feng Zhang (nascido em 22 de outubro de 1981) é um bioquímico sino-americano. Zhang atualmente detém a Cátedra James and Patricia Poitras em Neurociência no Instituto McGovern para Pesquisa do Cérebro e nos departamentos de Ciências do Cérebro e Cognitivas e Engenharia Biológica no Instituto de Tecnologia de Massachusetts.
Feng Zhang is a neuroscientist and molecular engineer who developed CRISPR tools for genome editing and diagnostics. He is a professor at MIT, a core member of the Broad Institute, and an investigator at the Howard Hughes Medical Institute.
28 de jun. de 2023 · Feng Zhang and his team at MIT and Harvard have uncovered a RNA-guided DNA-cutting enzyme in eukaryotes, Fanzor, that can edit the human genome. Fanzor is based on a protein that evolved from bacteria and has the potential to be more precise and deliverable than CRISPR/Cas systems.
